Publications

Show All

Kohli R, and Setchell KDR. Let the bile flow! Hepatology 2015 Sep 22. doi: 10.1002/hep.28244. [Epub ahead of print].

Asai A, Kohli R. Familial Homozygous Hypercholesterolemia–when to turn to transplant? Pediatric Transplant. 2015 Sep;19(6):577-9.

Kohli R, Myronovych A, Tan BK, Salazar-Gonzales RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KDR. Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH? Dig Dis, 2015;33(3):440-6.

Bolton SM, Campbell KM, Kukreja M, Kohli R. Neurologic Outcome of Urea Cycle Disorder Liver Transplant Recipients May Be Predicted by Pre-Transplant Neurological Imaging. Pediatric Transplant 2015 Aug;19(5):527-30.

Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine C, Feldstein AE, Alkhouri N. The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease. Dig Dis Sci Dig Dis Sci. 2015 May;60(5):1440-7.

Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N. Improvement in Liver Histology Is Associated With Reduction in Dyslipidemia in Children With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2015 Mar; 60(3):360-367.

Kramer JA, Grindley J, Makaron L, Kohli R, Kirby M, Mansfield KG, Wachtman LM. The Common Marmoset as a Model for the Study of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Veterinary Pathology. 2015 Mar; 52(2):404-13.

Mansoor S, Yerian L, Kohli R, Xanthakos S, Angulo P, Ling S, Lopez R, Christine C, Feldstein AE, Alkhouri N. The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease. Dig Dis Sci. 2014 Dec 25. [Epub ahead of print].

Myronovych A, Salazar-Gonzales RM, Ryan KK, Miles L, Zhang W, Jha P, Wang L, Setchell KDR, Seeley RJ, Kohli R. The Role of Small Heterodimer Partner (SHP) in NAFLD Improvement after Vertical Sleeve Gastrectomy in Mice. Obesity. 2014 Nov; 22(11):2301-11.

Prasad V, Chirra S, Kohli R, Shull GE. NHE1 deficiency in liver: implications for non-alcoholic fatty liver disease. Biochem Biophys Res Commun. 2014 Jul 25; 450(2):1027-31.
 
Begg D, Steinbrecher K, Mul J, Chambers A, Kohli R, Haller A, Cohen M, Woods SC, Seeley RJ. Effect of guanylate cyclase-C activity on energy and glucose homeostasis. Diabetes. 2014 Nov; 63(11):3798-804.

Mehta M, Slaughter C, Xanthakos SA, Kohli R. High Prevalence of Hepatitis B Non-Immunity in Pediatric Non Alcoholic Fatty Liver Disease Patients. Digestive and Liver Disease. 2014 Aug; 46(8):760-1.

Habegger KM, Al-Massadi O, Heppner KM, Myronovych A, Holland J, Berger J, Yi CX, Gao Y, Lehti M, Ottaway N, Amburgy S, Raver C, Müller TD, Pfluger PT, Kohli R, Perez-Tilve D, Seeley RJ, Tschöp M. Duodenal Nutrient Exclusion Improves Metabolic Syndrome and Stimulates Villus Hyperplasia. Gut. 2014 Aug; 63(8):1238-46.

Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Wilson-Pérez HE, Sandoval DA, Kohli R, Bäckhed F and Seeley RJ. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. May 8 2014; 509(7499):183-8.
Featured in: 
-- Kuipers F and Groen AK. FXR: the key to benefits in bariatric surgery? Nat Med. 2014 Apr; 20(4):337- 38. 
-- NIDDK website.
-- Wood NJ. Obesity. Beneficial effects of bariatric surgery are mediated by FXR signaling. Nat Rev Gastroenterol Hepatol. 2014 May; 11(5):267.

Harley ITH, Stankiewicz TE, Softic S, Giles DA, Flick ML, Cappelletti M, Xanthakos SA, Steinbrecher KA, Sartor BR, Budelsky AL, Kohli R, Karp CL and Divanovic S. IL-17 signaling accelerates the progression of non-alcoholic fatty liver disease. Hepatology. 2014 May; 59(5):1830-9.

Ryan KK, Tremaroli V, Clemmensen C, Kovatcheva-Datchary P, Myronovych A, Wilson-Pérez HE, Sandoval DA, Kohli R, Bäckhed F and Seeley RJ. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature. 2014 May 8;509(7499):183-8.

Mehta M, Slaughter C, Xanthakos SA, Kohli R. High Prevalence of Hepatitis B Non-Immunity in Pediatric Non Alcoholic Fatty Liver Disease Patients. Dig Liver Dis. 2014 Aug;46(8):760-1. 

Kohli R
. There’s More under the Nonalcoholic Fatty Liver Disease Umbrella Than an Elevated Alanine Aminotransferase Level. J of Pediatr. 2014 Apr; 164(4):684-6.

Habegger KM, Al-Massadi O, Heppner KM, Myronovych A, Holland J, Berger J, Yi CX, Gao Y, Lehti M, Ottaway N, Amburgy S, Raver C, Müller TD, Pfluger PT, Kohli R, Perez-Tilve D, Seeley RJ, Tschöp M. Duodenal Nutrient Exclusion Improves Metabolic Syndrome and Stimulates Villus Hyperplasia. Gut. 2014 Aug; 63(8):1238-46.

Ibrahim S, Gores GJ, Hirsova P, Kirby M, Miles L, Jaeschke A, Kohli R. MLK3-/- mice are protected against the development of high fat high carbohydrate diet-induced steatohepatitis. Liver Int. 2014 Mar; 34(3):427-37.

Harley ITH, Stankiewicz TE, Softic S, Giles DA, Flick ML, Cappelletti M, Xanthakos SA, Steinbrecher KA, Sartor BR, Budelsky AL, Kohli R, Karp CL and Divanovic S. IL-17 signaling accelerates the progression of non-alcoholic fatty liver disease. Hepatology. 2014 May; 59(5):1830-9.

Myronovych A, Kirby M, Ryan KK, Zhang W, Jha P, Setchell KDR, Dexheimer PJ, Aronow B, Seeley RJ, Kohli R. Vertical sleeve gastrectomy in obese mice increases serum bile acids while reducing liver steatosis in a weight-loss-independent manner.  Obesity. 2014 Feb; 22(2):390-400.

Xanthakos SA, Podberesky DJ, Serai S, King E, Balistreri WF, Kohli R. Use of magnetic resonance elastography to non-invasively assess hepatic fibrosis in pediatric chronic liver disease. J of Pediatrics. 2014 Jan; 164(1):186-8.

 

Kohli R, Seeley RJ. The search for the mechanisms of bariatric surgery. Nature Reviews. 2013 Oct; 9(10):572-4. 

Foster M, Softic S, Caldwell J, Kohli R, de Kloet A, and Seeley RJ. Subcutaneous Adipose Tissue Transplantation in Diet-Induced Obese Mice Attenuates Metabolic Dysregulation While Removal Exacerbates It. Physiological Reports. 2013 Aug;1(2). pii: e00015.

Gadang V, Kohli R, Myronovych A, Hui D, Perez-Tilve D, Jaeschke A. MLK3 promotes the development of metabolic dysfunction induced by saturated fatty acid-enriched diet. Am J Physiol Endocrinol Metab. 2013 Aug; 305(4):E549-56.

Kohli R, Setchell KDR, Kirby M, Ryan KK, Berger J, Softic S, Zhang W, Toure M, Parks K, Smith K, Seeley RJ. A Novel Surgical Model in Obese Rats Uncovers Endoplasmic Reticulum Hepatoprotective Effects of Bile Acids Post-Bariatric Surgery. Endocrinology. 2013 Jul; 154(7):2341-51.
-- Accompanying Editorial - Pournaras DJ, le Roux CW. Are bile acids the new gut hormones? Lessons from weight loss surgery models. Endocrinology. 2013 Jul;154(7):2255-6.
-- Featured in Nature Reviews as a “Research Highlights” article: Wilson C. Obesity: Bile acids and bariatric surgery. Nat Rev Endocrinol. 2013 May 7;9(7):379.

DeVore S*, Kohli R*, Lake K, Nicholas L, Dietrich K, Balistreri WF, Xanthakos SA. A Multidisciplinary Clinical Program is Effective in Stabilizing BMI and Reducing Transaminase Levels in Pediatric Patients with NAFLD. J Pediatr Gastroenterol Nutr. 2013 Jul; 57(1):119-23.

Kohli R*, Bradley D*, Setchell KDR, Eagon C, Klein S. Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids. J Clin Endocrinol Metab. 2013 Apr; 98(4):E708-12.

Bramlage K, Bansal V, Xanthakos SA, Kohli R. Nonalcoholic Fatty Liver Disease in Children- what should one do? Ind J Pediatr. 2013 Mar; 80 (Suppl 1):S109–S114.

Stefater M, Kohli R, Inge TH. Advances in the Surgical Treatment of Morbid Obesity. Mol Aspects Med. 2013 Feb; 34(1):84-94.

Squires J, Sisk RA, Balistreri WF, Kohli R. Isolated Unilateral Cytomegalovirus Retinitis: Rare Long-Term Complication after Pediatric Liver Transplantation. Pediatr Tran. 2013 Feb; 17(1):E16-9.

Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ. Fibroblast growthfactor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in rats. Endocrinology. 2013 Jan; 154(1):9-15.

 

Minar P, Alonso MH, Smith MT, Kohli R. An adolescent girl with belly pain… one gall bladder too many? J Pediatr Gastroenterol Nutr. 2012 Dec; 55(6):e142. 

Gaitonde S, Kohli R, Seeley RJ. The role of the gut hormone GLP-1 in the metabolic improvements caused by Ileal Transposition. J of Surg Res. 2012 Nov; 178(1):33-9.

Xanthakos SA, Kohli R. Treating Pediatric NAFLD with Cysteamine – is Adiponectin the Key? J of Pediatr. 2012 Oct; 161(4):639-45.e1. 

Xanthakos SA,Kohli R. Pediatric Non-alcoholic Fatty Liver Disease:Prevalence, Diagnosis, Risk factors, and Management. Clinical Liver Dis. 2012 Aug; 1(4): doi: 10.1002/cld.75.

Softic S, Kirby M, Berger N, Shroyer N, Woods SC, Kohli R. Insulin Concentration Modulates Hepatic Lipid Accumulation in Mice in part via Transcriptional Regulation of Fatty Acid Transport Proteins. PLOS One. 2012;7(6):e38952.

Bedel A, Hemmelgarn T, Kohli R. Comparison of Valganciclovir versus Ganciclovir for CMV prophylaxis in Pediatric Liver Transplant Recipients- A Single Center Study . Liv Transpl. 2012 Mar;18(3):347-54.

 

Foster MT, Shi H, Softic S, Kohli R, Seeley RJ and Woods SC. Visceral Adipose Transplantation-Induced Improvements in Glucose Tolerance in Mice: Alterations in Liver Fat Metabolism. Diabetologia. 2011 Nov;54(11):2890-9.
 
 Bansal V, Kohli R. Peutz Jeghers Syndrome. Review for Emedicine.com.
 
Kohli R, Feldstein AE. Animal Models of NASH: Are we there yet? J of Hepatology. 2011 Oct; 55(4):941-3.

Kohli R, Stefater M, Inge TH. Molecular Insights from Bariatric Surgery. Reviews in Endo Metab Disord. 2011 Sep;12(3):211-7.

Ibrahim SH, Kohli R, Gores GJ. Mechanisms of Lipotoxicity in NAFLD and Clinical Implications. J Pediatr Gastroenterol Nutr. 2011 Aug; 53(2):131-40.

Brunt EM et al for NASH Clinical Research Network. NAFLD activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011 Mar; 53(3):810-20.

Carter-Kent C, Brunt EM, Xanthakos SA, Kohli R, Whitington PF, Angulo P, Feldstein AE. The Relationships of Steatosis Type, Grade, and Zonality with Histological Features in Pediatric Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2011 Feb; 52(2):190-197.

Kohli R. Indian Childhood Cirrhosis - Revisited. J of Pediatr. 2010 Nov; 157, 766.

Kohli R, Kirby M, Setchell KDR, Jha P, Klustaitis K, Woollett LA, Pfluger PT, Balistreri WF, Tso P, Jandacek RJ, Woods SC, Heubi JE, Tschoep MH, D’Alessio DA, Shroyer NF, Seeley RJ. Intestinal adaptation after ileal interposition surgery increases bile acid recycling and protects against obesity related co-morbidities. Am J Physio. 2010 Sep; 299: G652 - G660.

Kohli R, Kirby M, Xanthakos SA, Softic S, Feldstein AE, Saxena V, Tang PH, Miles L, Miles MV, Balistreri WF, Woods SC, Seeley RJ. High-Fructose-Diet Induces Hepatic Fibrosis and Elevates Plasma Oxidized Coenzyme Q9 in a Novel Murine Model of Obesity and NASH. Hepatology. 2010 Sep; 52(3):934-44.

Kohli R, Boyd T, Lake K, Dietrich K, Nicholas L, Balistreri WF, Ebach D, Shashidhar H, Xanthakos SA. Progression of Nonalcoholic Steatohepatitis in childhood. J Pediatr Gastroenterol Nutr. 2010 Apr; 50(4):453-6.

 

Scientific Presentations & Invited Talks

Show All
Invited Faculty and Speaker - NASPGHAN First Year’s Fellow’s Conference, Weston, FL. Using a research project to launch your career.
Invited Speaker - Annual NASPGHAN Scientific Meeting, Atlanta, GA. Treatment of NASH in Children.

Invited Speaker - Department of Pediatrics Grand Rounds, University of Florida, Gainesville, FL. Liver Disease as a Complication of Obesity.

Diseases Week, Chicago, IL: Invited Speaker - The Biology of Bariatric Surgery: Translational Symposium - AGA. Bile Acids & the Regulation of Energy Balance.

Invited Speaker - 4th Annual Cincinnati Diabetes & Obesity Center Symposium, Cincinnati, OH. Mechanisms of metabolic improvements after bariatric surgery.

Invited Speaker - 14th Annual Levine Diabetes & Obesity Symposium Digestive, City of Hope, Pasadena, CA. Perspectives on the metabolic improvements of bariatric surgery.

Invited Speaker - Department of Pediatrics Grand Rounds, Wayne State University, Detroit, MI. Liver Disease as a Complication of Obesity.

Medical Student Lecturer - 3rd Year Medical Students, University of Cincinnati College of Medicine, Cincinnati, OH. Treating Obesity with Bariatric Surgery- what does bile have to do with it? 

Invited Speaker - Bone Marrow Transplant and Immune Deficiency Seminar Series, Cincinnati Children's. Nonalcoholic fatty liver disease: should we be screening after cancer treatment?

Oral Presentation - XXIII International Bile Acid Meeting, Freiburg, Germany. An Intact Fgf15 Signaling Pathway is Necessary for Hepatoprotection after Bariatric Surgery. Bile Acids as Signal Integrators and Metabolic Modulators.

Oral Presentation - The Obesity Society Meeting, 2nd Annual Obesity Symposium, Boston, MA. The role of Short Heterodimer Partner (SHP) in liver outcomes after Sleeve Gastrectomy in Obese Mice.

Invited Speaker - Visiting Young Investigator Series - Baylor College of Medicine, Houston TX. Bariatric Surgery and NASH: The role of bile acids and FXR-SHP signaling.

Invited Speaker - Synageva Sponsored Satellite Breakfast Symposium at NASPGHAN. Fatty Liver Disease: It’s Not All Related to Obesity.

Invited Speaker - 23rd Annual Pediatric Gastroenterology, Hepatology, and Nutrition Conference, Pune, India. Mitochondrial Hepatopathies: Are Hepatologists missing it?

Invited Speaker - Pediatric Residents’ Noon Conference, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. Nonalcoholic Fatty Liver Disease in Children.

Digestive Diseases Week, Orlando, FL:
Invited Speaker- Luminal Regulators of Weight and Metabolic Function: Research Symposium, American Gastroenterology Association. Can Bile Acids Replace Bariatric Surgery?

Invited Speaker - Metabolic Diseases Institute Colloquium, University of Cincinnati. Can Bile Acids Replace Bariatric Surgery?
Invited Speaker - Department of Pediatric Gastroenterology, University of California, San Diego, CA. Living Related Liver Transplantation: Can Children Do Without?

Invited Speaker - Department of Dietetics, Christ Hospital, Cincinnati, OH. Nonalcoholic Fatty Liver Disease in Children.

 

Invited Speaker - Annual NASPGHAN Scientific Meeting, Salt Lake City, UT. Nonalcoholic Fatty Liver Disease in Children.

Invited Speaker - Annual Clinic Days, Wayne State University, Detroit, MI. Nonalcoholic Fatty Liver Disease in Children.

Invited Speaker - Paediatric Liver GI Nutrition Center, King’s College Hospital, London, UK. Nonalcoholic Fatty Liver Disease and Bariatric Surgery in Children.

Invited Speaker - Digestive Diseases Week, San Diego, CA. Mechanisms of Bariatric Surgery: Research Symposium, American Gastroenterology Association.

Invited Speaker - Department of Pediatrics Grand Rounds, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH. Liver Disease as a Complication of Obesity.

Abstract Presentation - Keystone Obesity and Type 2 Diabetes Meeting, Santa Fe, NM. Role of IL-17 in the development and progression of non-alcoholic fatty liver disease.
Abstract Presentations- AASLD - 2011 San Francisco, CA:
• Oral Presentation- NASH Parallel Session: Choledocho-Jejunal Bile Diversion in Obese Rats Increases Serum Tauro-urso-deoxy-cholic acid (TUDCA) Levels & Concomitantly Reduces Hepatic Steatosis;
• Poster Presentation- NASH Poster Session: The Nox4-GSH Pathway Mediates Fibrosis in a Murine Model of Fibrotic Nonalcoholic Steatohepatitis (NASH);
• Poster Presentation- NASH Poster Session: Serum oxidized Coenzyme Q levels are associated with severity of ballooning in biopsy confirmed pediatric nonalcoholic fatty liver disease
• Poster Presentation- Pediatric Liver Disease Session: Retrospective review of the incidence of cytomegalovirus infection and disease post liver transplantation in pediatric patients: Comparison of prophylactic oral ganciclovir versus oral valganciclovir.

Invited Speaker- Department of Pediatric Gastroenterology, Yale University School of Medicine, New Haven, CT. The Role of Bile Acids in Bariatric Surgery. 2011.

Invited Speaker - Ethicon Endo-Surgery Sponsored Symposium at American Society of Metabolic and Bariatric Surgery Annual Meeting, Orlando, FL. Ileal Interposition to new Procedure Development. 2011.
 
Invited Speaker and Session Moderator - Ethicon Endo Surgery’s Metabolic Applied Research Strategy Annual Meeting, Massachusetts General Hospital, Boston, MA. 2011.

Invited Speaker - Neuroendocrinology of Obesity and Stress Seminar Series, Metabolic Disease Institute, University of Cincinnati. Role of bile acids in bariatric surgical procedures. 2011.

Invited Speaker - Cincinnati Diabetes and Obesity Center Research Retreat. Insulin Signaling and Fat Transport in the Liver. 2011.

Abstract Presentations - Digestive Diseases Week, 2011. Chicago, IL:
• AASLD Plenary Session: The Hepatic Inflammasome Has an Increased NK-T and CD8+ T- Cell Signature in a Murine Model of Fibrotic Nonalcoholic Steatohepatitis (NASH)
• AGA Poster Presentation: Choledocho-Jejunal Bile Diversion Protects Against Obesity Related Co-Morbidities by Increasing Serum Bile Acid and GLP-1 Levels

Invited Speaker - Fluxes and Barriers Research Seminar Series, Department of Physiology, University of Cincinnati College of Medicine. 2011.

Abstract Presentation - Keystone Obesity and Type 2 Diabetes Meeting, Keystone, CO. Short-Circuiting of the Bile Acid Entero-Hepatic Circulation via a Choledocho-Jejunal Bile Diversion Reduces Obesity Related Co-morbidities. 2011.

Invited Speaker - Type-2 Diabetes Meeting, Johnson & Johnson, New Delhi, India. Increased frequency of bile acid cycling causes T2DM remission and excess weight loss. 2010.

Oral Presentation - Global Obesity Summit (Travel Award to Post-Doctoral Fellow), University of Mississippi Medical Center, Jackson, Mississippi. 2010.

Abstract Presentation - Annual AASLD Scientific Meeting, Boston. Insulin Signaling Mediates Hepatic Steatosis through Fatty Acid Transport Proteins (FATPs) in a U-Shaped Dose Dependent Manner. 2010.

Oral Presentation - Annual NASPGHAN Scientific Meeting, New Orleans. Hepatic Steatosis in Type 2 and Type 1 Diabetes Mellitus is Mediated by Insulin Signaling via Fatty Acid Transport Proteins. 2010.

Invited Speaker - Digestive Health Center Seminar Series, University of Cincinnati. CoEnzyme Q in the Pathogenesis of NAFLD. 2010.  

Invited Speaker - 20th Annual Pediatric Gastroenterology, Hepatology and Nutrition Conference, Post Graduate Institute of Medical Education & Research, Chandigarh, India. 2010.

Invited Speaker - Department of Gastroenterology Research Seminar Series, University of Cincinnati. Non-alcoholic Fatty Liver Disease. 2010.

Invited Speaker - Chacha Nehru Bal Chikitsalaya, New Delhi, India. Complications of Chronic Liver Disease in Children. 2010.

Patents

Biomarkers and Methods for Determining Disease Progression in Nonalcoholic Steatohepatitis (NASH). USPTO Application #20110212468; 13/014,580; Patent allowed July 2014.

Grants

Show All
Clinical Research Network in Nonalcoholic Steatohepatitis. Site Co-Principal Investigator. NIH/NIDDK U01 DK08505. 07/01/09 - 06/30/15.

Research Innovation Award to study the role of bile acid physiology after murine & adolescent vertical sleeve gastrectomy. Principal Investigator. NASPGHAN Foundation. 11/15/13-11/14/15.

NAFLD Improvement after Bariatric Surgery: The role of bile acid signaling. Principal Investigator. NIH/NIDDK 1R01DK100314-01A1. 04/01/2015 - 03/31/2020.
Research Innovation Pilot Grant to study The Role of SHP signaling after vertical sleeve gastrectomy. Principal Investigator. Cincinnati Children’s Research Foundation. 10/01/13 - 09/30/14.

CDOC Pilot Grant to study  the benefit of NHE1 inhibition on liver physiology specifically liver steatosis. Co-investigator. University of Cincinnati. 10/01/13 - 06/14/14.

The goal of this project is to validate Co enzyme Q as a companion diagnostic for the proprietary NASH therapeutic that Galectin Pharmaceuticals is testing in a phase 2 trial. PPD Global Central Labs. 03/01/13 - 11/30/14.

Contact Us

Phone: 513-803-7044
Fax: 513-803-2785